eClinical Tech News

Kyverna Therapeutics is moving to file a BLA in the first half of 2026 for miv-cel (mivocabtagene autoleucel, KYV-101)...

Inhibikase Therapeutics has initiated IMPROVE-PAH, a global, adaptive pivotal Phase 3 program of IKT-001 in pulmonary arterial hypertension, with...

Zenas BioPharma has launched concurrent underwritten offerings of convertible senior notes due 2032 and common stock, including 30-day overallotment...

MoonLake Immunotherapeutics reported Week 40 results from its twin Phase 3 VELA trials of sonelokimab in moderate-to-severe hidradenitis suppurativa,...

Cue Biopharma has appointed Lucinda Warren as interim president and chief executive officer, effective March 26, 2026, following the...

Entera Bio has submitted a streamlined Phase 3 protocol to FDA for EB613, an oral PTH(1-34) anabolic tablet for...

Exicure reported 2025 results that underscore a high-stakes pivot and a narrowing runway. Cash and equivalents fell to $3.7...

Maze Therapeutics reported positive topline results from its Phase 2 HORIZON study of MZE829 in patients with broad APOL1-mediated...

BioCardia reported 2025 results and a slate of regulatory and clinical milestones that could pull cardiac cell therapy back...

Sellas Life Sciences signaled a catalyst-heavy 2026, reporting year-end 2025 financials while positioning two late-stage AML programs for pivotal...